



EINSTEIN

Albert Einstein College of Medicine

Montefiore

Fourth Einstein-Montefiore Presidential Lecture

Wednesday, June 15, 2022

4:30 - 6:00 PM

Robbins Auditorium



Welcome to the fourth Einstein-Montefiore Presidential Lecture, which we've established to highlight outstanding research being pursued at Einstein and Montefiore. Each year, a speaker from each institution will share work celebrating our partnership in innovative research.

Philip O. Ozuah, M.D., Ph.D.

President and Chief Executive Officer
Montefiore Medicine

Gordon F. Tomaselli, M.D.

The Marilyn and Stanley M. Katz Dean
Albert Einstein College of Medicine
Executive Vice President and Chief Academic Officer
Montefiore Medicine

INTRODUCTION

Maureen Charron, Ph.D., *Faculty Interactions Committee*
Professor, Biochemistry; Obstetrics & Gynecology and
Women's Health; Medicine

WELCOMING REMARKS

Philip O. Ozuah, M.D., Ph.D.
President and Chief Executive Officer, Montefiore Medicine

INTRODUCTION OF ULRICH STEIDL, M.D., PH.D.

Gordon F. Tomaselli, M.D.
The Marilyn and Stanley M. Katz Dean, Albert Einstein College of Medicine
Executive Vice President and Chief Academic Officer, Montefiore Medicine

*Understanding the Molecular and Cellular Pathogenesis of Myeloid
Malignancies at the Stem Cell Level*

Ulrich Steidl, M.D., Ph.D.
Professor, Cell Biology; Medicine
Deputy Director, Montefiore-Einstein Cancer Center (MECC)
Interim Director, Ruth L. and David S. Gottesman Institute for Stem Cell
Biology and Regenerative Medicine

INTRODUCTION OF AMIT VERMA, M.B.B.S.

Gordon F. Tomaselli, M.D.
Therapeutic Targeting of MDS and AML

Amit Verma, M.B.B.S.
Professor, Medicine; Developmental and Molecular Biology
Associate Director, Translational Science, MECC
Director, Division of Hemato-Oncology

Reception: Max and Sadie Friedman Upper Lounge



Ulrich Steidl, M.D., Ph.D.

Dr. Steidl is professor of cell biology and of medicine, deputy director of the Montefiore-Einstein Cancer Center (MECC), and interim director of the Ruth L. and David S. Gottesman Institute for Stem Cell Biology and Regenerative Medicine. His research has focused on the earliest origins of myeloid malignancies, and he has made fundamental discoveries, particularly in the areas of pre-cancerous stem cells and transcriptional dysregulation. In close collaboration with Dr. Verma's laboratory, Dr. Steidl's group identified novel targets and drugs directed against pre-cancerous and cancer stem cells in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), many of which have been translated into the clinic, with the ultimate goal of "precision prevention" of these deadly diseases. His work has been recognized by numerous honors including an Outstanding Investigator Award from the National Cancer Institute. He is also current president-elect of the International Society of Experimental Hematology (ISEH) and will assume the ISEH presidency later this year.



Amit Verma, M.B.B.S.

Dr. Verma is professor of medicine and of developmental and molecular biology, associate director of translational science at MECC, and director of the division of hemato-oncology at Montefiore and Einstein. His lab has been involved in studying the pathogenesis of myeloid malignancies such as MDS and AML. Research from his lab has elucidated the critical role of various signaling pathways (p38 MAP kinase, TGF-beta, smad2/3, IRAK, and others) in MDS and this work has directly led to the therapeutic targeting of these pathways in clinical trials in MDS/AML. In close collaborations with Dr. Steidl, Dr. Verma has defined stem cell alterations in MDS/AML and translated these findings to the clinic. He has also conducted clinical studies in hematologic malignancies that have examined the effects of COVID-19 and environmental exposures on outcomes and pathogenesis of blood cancers.
